L'Oreal (LORA) AI Stock Analysis
L'Oreal
(Frankfurt:LORA)
No summary available
L'Oreal (LORA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 258.71B
- Dividend Yield
- 1.67%
- Average Volume (3M)
- 18
- Price to Earnings (P/E)
- 37.0
- Beta (1Y)
- 0.35
- Revenue Growth
- 3.46%
- EPS Growth
- 3.19%
- Country
- Germany
- Employees
- 94,610
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
L'Oreal Business Overview & Revenue Model
Company Description
L'Oréal S.A., a prominent global enterprise, specializes in the development, production, and worldwide distribution of a diverse range of cosmetic and personal care goods catering to both male and female consumers. Its business activities are structu...
L'Oreal Earnings Call Summary
The call emphasized multiple strong operational achievements: robust adjusted like‑for‑like growth (6.5%), record operating margin (21.3%), high e‑commerce growth (18% to EUR 7.4bn), strong division and regional performance (Professional +11.6%, Derm +10.6%, SAPMENA +13.8%), and solid cash generation (operating net cash flow +13.9%). Key challenges were manageable but notable: FX headwinds (-2.8%), sizeable nonrecurring charges (-EUR 430m), heavier A&P investment (+70bps), increased net debt and cash outflows for acquisitions/dividends (free cash flow impact), and accounting/amortization dilution from the Galderma stake (USD ~450m p.a. PPA impact). Overall, the positives (broad growth, record margins, innovation and e‑commerce momentum, clear plan to keep investing) outweigh the negatives, which are largely strategic investments, timing effects and accounting impacts rather than indications of a structural earnings deterioration.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance highlights: management expects the global beauty market to grow about 4–5% for full‑year 2026 and says L’Oréal will continue to outperform that market; the exchange‑rate impact extrapolated from June 30 is a -0.6% hit to full‑year sales (an improvement versus the -2.5% assumed at the start of the year); year‑end financial leverage is expected to be below 1.0x (vs. 1.2x at end‑June), with net debt €12.7bn and gearing 37.4% at June 30; full‑year net financial expenses are guided to be roughly €400m; Galderma purchase‑price amortization of about USD 450m p.a. will reduce reported Galderma earnings and contribute to near‑term dilution (group EPS slightly negative in 2026 before returning to small growth in 2027), and Kering consolidation is estimated to be a small (~10bp) margin drag at group level in H2; management signalled continued reinvestment behind innovation (A&P up 70bps to 32.6% in H1) while keeping R&I at ~2.8% of sales and capex around 3% (H1 €760m), with strong cash generation (operating net cash flow H1 €3.1bn, +13.9%); July trading was described as “a very good start.”
L'Oreal Peers Comparison
Overall Rating
PG72Outperform
KVUE70Outperform
UL64Neutral
EL58Neutral
COTY57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PG | 72Outperform | $374.48B | 23.94 | 29.55% | 2.68% | 3.52% | -3.74% |
| KVUE | 70Outperform | $37.09B | 21.94 | 16.06% | 5.40% | 3.50% | 17.82% |
| UL | 64Neutral | $140.47B | 13.70 | 58.26% | 3.41% | -17.45% | 8.84% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| EL | 58Neutral | $39.58B | 214.18 | 4.63% | 1.28% | 5.51% | ― |
| COTY | 57Neutral | $2.99B | -4.88 | -18.06% | ― | -1.46% | -60.87% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LORA | L'Oreal SA | 84.00 | 14.98 | 21.71% | |
| EL | Estée Lauder | 109.23 | 17.65 | 19.28% | |
| PG | Procter & Gamble Company | 161.57 | 18.55 | 12.97% | |
| UL | Unilever plc | 65.26 | 2.29 | 3.63% | |
| COTY | Coty Inc | 3.40 | -0.43 | -11.23% | |
| KVUE | Kenvue, Inc. | 19.31 | 4.25 | 28.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.